24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Resources
Basic InformationLookupsLatest News
When Is It Time for a Knee Replacement?AHA News: Death Rates From Tears In This Major Heart Artery Are Rising, Especially Among Women, Black AdultsOmicron COVID Causing Severe Croup in Young Children'Zapping' Air Passages May Bring Relief for Severe AsthmaModerna Asks FDA to Approve Second Booster for All AdultsNew Tick-Borne Virus Is Spreading Across U.S.Memory Issues Plague Long COVID PatientsCOVID Vaccine Won't Cause Rare Neuro Events, But COVID Infection CouldTriglycerides a Stroke Danger, Even With Statin TreatmentIt Can Take Weeks for Some Patients With Severe COVID to Recover ConsciousnessOmicron Wave Had 5 Times as Many Small Kids Hospitalized Compared to DeltaBreathing Dirty Air Could Raise Your Odds for Rheumatoid ArthritisPalliative Care Crucial After Severe Stroke, But Many Patients Miss OutMammograms Can Also Highlight Heart Risks: StudyPfizer Asks FDA to Approve Second Booster for SeniorsEven a Little Light in Your Bedroom Could Harm HealthMental Issues Can Linger More Than a Year After Severe COVIDRise in U.K. COVID Cases Closely Watched by U.S. Health OfficialsLong COVID May Bring Long-Term Lung DamageNew Malaria Treatment Gets First Approval for Use in ChildrenWarming World Means More Cases of Dangerous Low-Salt ConditionAbout 1 in 6 U.S. Couples Disagrees on COVID VaccinationCOVID Meds Appear to Work Against BA.2 Omicron Variant‘Deltacron’ Variant Rare and Not a Major ConcernCould Depression Make Dry Eye Worse?When Will Americans With Diabetes Get Relief From High Insulin Prices?COVID's Global Death Toll May Be 3 Times Official NumbersDrug Could Be Non-Antibiotic Alternative to Treat UTIsFlu Vaccine No Match for Circulating Variants This SeasonLymphedema in Legs Strikes 1 in 3 Female Cancer SurvivorsScience Brings Shortcut to Spotting 50 Rare Genetic DiseasesU.S. Airplane, Train and Transit Mask Mandates Extended to April 18Man Who Received First Pig Heart Transplant Has DiedPfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17Could a Stool Test Help Spot Pancreatic Cancer?Upcoming Surgery Worry You? Poll Says You're Not AloneHalf of Americans Live With Legacy of Childhood Lead PoisoningIn Reversal, WHO Now Supports COVID BoostersLooking to Neanderthals to Explain Today's Lower Back PainWhat's More Accurate, Blood Pressure Readings at Home or Doctor's Office?Begin Now to Protect Your Heart as Clocks 'Spring Forward'Brain Changes May Fuel 'Long COVID' Anxiety, ConfusionAHA News: Break Up Binge-Watching by Taking a StandHow COVID-19 Can Change the BrainHeart Defects Could Raise Odds for Severe COVID-196 Healthy Steps to Preventing Colon CancerAHA News: These Three Risk Factors May Have the Biggest Impact on Dementia CasesU.S. Surgeon General Investigates COVID-19 MisinformationLong or Irregular Periods May Put a Woman's Liver at RiskCould Your Blood Type Make COVID Worse?
Questions and AnswersLinks
Related Topics

Diabetes

Another Study Finds Vaccine Booster 'Neutralizes' Omicron

HealthDay News
by Robert Preidt
Updated: Jan 20th 2022

new article illustration

THURSDAY, Jan. 20, 2022 (HealthDay News) -- If you need more proof that a third shot of COVID vaccine is needed, new British research confirms that boosters can "neutralize" the virus' Omicron variant.

To arrive at that conclusion, they analyzed 620 blood samples from 364 health care workers and staff at the Francis Crick Institute and the National Institute for Health Research UCLH Biomedical Research Centre, in London.

People who had received only two doses of either the AstraZeneca vaccine or the Pfizer vaccine were less protected against the Omicron variant than against the Alpha and Delta variants. Antibody levels declined in the first three months after the second dose, but a third (booster) dose increased levels of antibodies that combat the Omicron variant.

In people who received the Pfizer vaccine for all three doses, antibody levels against Omicron after a third dose were similar to levels against Delta after two doses. Overall, antibody levels were nearly 2.5 times higher against Omicron after three doses than after two doses, the investigators found.

Higher levels of antibodies against the Omicron variant were also found in people who received two doses of either the AstraZeneca vaccine or the Pfizer vaccine and previously had COVID-19 symptoms, compared to those without previous COVID-19 symptoms.

Antibody levels alone do not predict vaccine effectiveness, but they are a good indicator of protection against severe COVID-19 and hospitalization, according to the team that conducted the research as part of what's known as the SARS-CoV-2 Legacy study.

"People who have queued outside vaccinations centers should be reassured that a vaccine booster is the best way of protecting them from Omicron. And for people who haven't yet had a booster or even a first dose, it's not too late," said Emma Wall, a UCLH infectious diseases consultant and senior clinical research fellow for the Legacy study.

"This new variant can overcome the immune blockade put in place by two vaccine doses, but thankfully following the third dose, neutralizing activity is robust in the vast majority of people. A third dose builds our defenses higher, making it harder for the virus to cause severe COVID-19," Wall explained in a Crick Institute news release.

The findings were published online Jan. 19 as a research letter in The Lancet medical journal.

"While the Omicron variant has considerably more mutations than other recent variants, such as Alpha and Delta, our data show that the boosters push our immune system to make a broad response capable of tackling it," said David Bauer, group leader of the Crick's RNA Virus Replication Laboratory and member of the U.K.'s Genotype-to-Phenotype National Virology Consortium.

Sonia Gandhi is Legacy chief investigator at Crick and a consultant neurologist at UCLH. She said, "Now that we have established that boosters are effective against the Omicron variant, future research will need to address the duration and persistence of this booster response. New variants of concern will continue to emerge as the pandemic evolves, so effective immune monitoring is needed to stay responsive and remain protected."

More information

For more on Omicron, go to the U.S. Centers for Disease Control and Prevention.

SOURCE: Francis Crick Institute, news release, Jan. 19, 2022